Blog

qordata thought leaders and subject matter experts share their insights and experiences

Ned Mumtaz
Written By
Ned Mumtaz
May 15, 2017
0 Comments

This message carries over from my last blog about my workshop at the PCC 2017. In that, I spoke briefly about why transparency/compliance professionals need to know the difference between symptoms and diseases when diagnosing pharma spend. Let’s start with an example. A KOL spend hike is a symptom, not a disease. Diminished profitability in a brand is again, a symptom, not a disease. CIAs (Corporate Integrity Agreements), are again, a symptom, not a disease. A symptom is something that troubles you, the pharma transparency professional. It is something not easily explained; something with a potentially negative result. But treating the symptom alone would be a shallow exercise. It’s difficult—but more rewarding—to probe deeper for the cause. How To Separate […]

Ned Mumtaz
Written By
Ned Mumtaz
May 15, 2017
0 Comments

At the 14th PCC last week, I was invited to lead a workshop on how to “Enhance Skill Sets and Improve Use of Data Analytics for Global Compliance Insights.” I was happy at the kind of questions and experiences my workshop’s participants raised. One area, in particular, I hope, will be a source of continuing interest and development. Using compliance to monitor pharma spend is an activity which has drawn more interest in the aftermath of Sunshine Payments. However, the concern most transparency/compliance professionals raise at my workshops is: Are we making the most of the resources at our disposal to ensure compliance activities feed directly into enhanced profitability and performance, and improved reputation? Below, I’ve outlined the basic steps […]

Nayyara Rahman
Written By
Nayyara Rahman
May 9, 2017
0 Comments

In one of our most effective webinars this year, Wendy Derosa and Bryan Timer, both Compliance professionals at Merck USA, had useful advice for small and mid-sized pharmaceutical companies just starting out in the analytics space. Here’s what they had to say. Start Small: Before the emigration to a sophisticated analytics platform, it helps to start small first. Even spreadsheet software can help you capture errors easily with filtering tools; the sorting function and so on. It’s a little harder to capture duplicates, given the number of transactions per month, and also the fact that similar HCP names may overlap and present a confusing story to anyone doing the process manually. Nonetheless, starting small is better than not starting a […]

Mohammad Ovais
Written By
Mohammad Ovais
April 25, 2017
0 Comments

While privacy laws in Europe show continuing evolution and attract views from both sides within the compliance/transparency space, another closely-related topic was under debate at the 7th Annual Global Transparency Reporting Congress in the UK. For transparency professionals, the decision to move towards pre-disclosure drew strong arguments from both sides. The Debate Not Ready For Pre-Disclosure As GDPR promises to award more privacy rights to physicians in Europe, does pre-disclosure make sense? One may argue against this, when considering the expenditure of time and funding this exercise demands. Even for drug and device companies ready to undertake the pre-disclosure exercise, accounting for the right technology, resources, and internal workflow are realistic, plausible obstacles. How would pre-disclosed data affect physician consent rates? […]

Upcoming Event

OOPS! NO UPCOMING EVENT

Ask an Expert

Get all the insights, and the answers to the most critical issues in pharma compliance from thought leaders in qorcommunity

ASK AWAY
OUR SOLUTIONS CAN SIMPLIFY YOUR COMPLIANCE EFFORTS.